Zobrazeno 1 - 10
of 501
pro vyhledávání: '"Napalkov, P."'
Autor:
A. I. Listratov, I. I. Ivanov, N. K. Ziskina, V. V. Efimenko, A. V. Zhavoronkova, E. S. Milyakova, A. A. Kudrjavtseva, D. A. Napalkov, A. A. Sokolova
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 20, Iss 4, Pp 401-408 (2024)
Aim. To assess the compliance of nephroprotective and anticoagulant therapy in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) with modern clinical guidelines.Material and methods. The study included patients with CKD in combi
Externí odkaz:
https://doaj.org/article/045088b52f354983b8aa8acc83d0ea18
Autor:
D. A. Napalkov, A. A. Sokolova, A. A. Kudrjavtseva, A. I. Skripka, A. V. Zhilenko, E. V. Kolpachkova, D. K. Varvarina
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 20, Iss 2, Pp 221-226 (2024)
Aim. To study the effect of dietary supplements containing omega-3 polyunsaturated fatty acids (Omega-3 PUFAs) on the parameters of ambulatory blood pressure monitoring (ABPM), 24-hour electrocardiogram (HM-ECG), and lipid profile in postmenopausal w
Externí odkaz:
https://doaj.org/article/08419b7fee4141cda8e2eac35faedac3
Publikováno v:
Российский кардиологический журнал, Vol 29, Iss 3S (2024)
Chronic kidney disease is one of the most important diseases in comorbid patients with cardiovascular disease. To reduce the risk of cardiovascular and renal complications, such patients should receive renin-angiotensin system inhibitors, statins and
Externí odkaz:
https://doaj.org/article/4f0c92139e13457ba5bb04e058e3a03e
Autor:
Dmitry A. Napalkov
Publikováno v:
Consilium Medicum, Vol 25, Iss 10, Pp 709-714 (2023)
Aim. To evaluate the effectiveness and tolerability of antihypertensive therapy with fixed combinations of telmisartan in patients with hypertension (Htn) in the presence or absence of metabolic syndrome (MS). Materials and methods. A total of 598
Externí odkaz:
https://doaj.org/article/83cf9318fb7d42a6bd3d680c576cb559
Autor:
A. A. Kudriavtseva, E. V. Kolpachkova, Z. A. Gebekova, T. A. Sadulaeva, A. A. Sokolova, D. A. Napalkov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 19, Iss 3, Pp 248-253 (2023)
The question of the safety of direct oral anticoagulants (DOACs), despite their high efficacy in the prevention of thrombotic events in atrial fibrillation (AF), remains relevant due to the risk of developing hemorrhagic events while taking standard
Externí odkaz:
https://doaj.org/article/1079f71d391a4d65bff475ca6bac1a01
Autor:
A. A. Sokolova, D. A. Napalkov
Publikováno v:
Российский кардиологический журнал, Vol 28, Iss 12 (2023)
The publication reflects the modern strategy and potential of various fixed-dose combinations in comorbid patients with hypertension and lipid metabolism disorders. Based on guidelines and key randomized studies, algorithms for prescribing combinatio
Externí odkaz:
https://doaj.org/article/ec038b5808354b5f893ffcbc51b517d1
Autor:
B. A. Tatarsky, D. A. Napalkov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 19, Iss 1, Pp 83-88 (2023)
Atrial fibrillation (AF) is strongly associated with stroke risk, but an association by itself does not necessarily imply causation. The question remains whether AF is a risk factor for stroke and whether treatment that reduces the severity of AF wil
Externí odkaz:
https://doaj.org/article/89974a7e9c4945089b52e90f281f1f9a
Autor:
A. N. Sumin, D. V. Duplyakov, F. I. Belyalov, A. E. Bautin, A. V. Bezdenezhnykh, S. V. Garkina, M. L. Gordeev, D. A. Zateishchikov, O. B. Irtyuga, E. V. Korok, T. Yu. Kulagina, E. A. Medvedeva, M. V. Menzorov, D. A. Napalkov, T. V. Pavlova, O. V. Petrunko, K. V. Protasov, Yu. S. Sibagatullina, N. A. Cherepanova, P. Sh. Chomakhidze, A. M. Shutov
Publikováno v:
Российский кардиологический журнал, Vol 28, Iss 8 (2023)
Russian Society of Cardiology (RCS)
Externí odkaz:
https://doaj.org/article/33506eea27bb4b418fc1f659bae18451
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 18, Iss 6, Pp 727-733 (2023)
Left ventricular thrombus (LVT) is a serious risk factor for systemic embolism development. Despite the evident danger of this condition, current guidelines describe management of patients with this potentially fatal complication very briefly. LVT ca
Externí odkaz:
https://doaj.org/article/9f2b2cbef88c4b6fb704f904450b9163
Autor:
Z. A. Gebekova, I. I. Ivanov, A. A. Kudrjavtseva, E. V. Kolpachkova, A. A. Sokolova, V. P. Sedov, D. A. Napalkov
Publikováno v:
Атеротромбоз, Vol 12, Iss 2, Pp 103-112 (2023)
Thromboembolic syndrome, the frequency of which is 8–15%, is the main danger for a patient with atrial fibrillation (AF). The left atrial appendage is the most common source of thromboembolia in atrial fibrillation. The frequency of detection of le
Externí odkaz:
https://doaj.org/article/efa6b7b95cef45c99220eb021c0f307e